Buy Braftovi Online

(Encorafenib)

The active ingredient in Braftovi is encorafenib. It belongs to a class of medications known as kinase inhibitor drugs that target the MEK pathway. It works by targeting abnormal proteins produced by certain mutated genes, including the BRAF V600E mutation. These proteins play a role in cancer cell growth and division. By blocking these signals, encorafenib helps slow or stop the spread of cancer cells in different parts of the body.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Braftovi. However, the following is a synopsis of the general guidelines for the use of Braftovi:

• Take Braftovi exactly as prescribed by your healthcare provider.
• It is usually taken by mouth once daily.
• It may be used as a single agent or in combination with other treatments such as binimetinib for metastatic melanoma or cetuximab for mCRC.
• Swallow capsules whole with or without food.
• Try to take your dose at the same time each day.
• If you miss a dose, take it as soon as you remember unless it is close to your next dose. Do not take two doses at once.

Some mild or the most common adverse reactions of Braftovi seen in clinical trials include:

• Fatigue.
• Nausea.
• Abdominal pain.
• Constipation.
• Arthralgia.
• Alopecia.
• Decreased appetite.
• Elevated liver enzymes, such as AST or alkaline phosphatase.

Some individuals may experience serious side effects while using Braftovi. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• New or worsening skin cancer, such as basal cell carcinoma or other cutaneous lesions.
• Signs of cardiomyopathy, such as shortness of breath or swelling.
• Eye problems such as uveitis.
• Heart rhythm problems such as QT prolongation.
• Severe bleeding or signs of infection.
• Allergic reactions.

These are not all of the possible side effects of Braftovi. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the U.S. Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Braftovi, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including if you have:

• A history of heart disease or cardiovascular conditions.
• Risk factors for QT prolongation.
• Liver disease or abnormal liver function tests, such as elevated AST or alkaline phosphatase.
• Eye conditions or vision problems.
• A history of skin cancer or dermatologic conditions.
• Any abnormalities in blood tests.
• A family history of cancer-related conditions.

Regular monitoring is required during treatment, including checks for abnormalities in blood tests and evaluation of response rate and objective response rate (ORR). Braftovi has limitations of use and should only be prescribed for patients with confirmed BRAF V600E mutation or V600K mutation. It is not effective in patients with wild-type BRAF mutation cancers, including wild-type BRAF melanoma or wild-type BRAF NSCLC. Testing for biomarkers such as the BRAF V600E mutant is required before starting treatment.

Braftovi should not be used in:

• Patients with a known severe allergic reaction to encorafenib or any component of the formulation.
• Patients without confirmed BRAF V600E mutation or related mutations, as treatment may not be effective.

The time it takes for Braftovi to work can vary depending on the type of cancer and the individual patient. Some patients may begin to see improvement in symptoms or tumor response within weeks, while others may take longer. Clinical outcomes such as response rate and overall survival are typically measured over several months during ongoing treatment. Regular follow-up with your oncology team is important to monitor progress. People taking Braftovi who may become pregnant should use effective contraception while taking the medication and continue using birth control for 2 weeks after treatment ends.

When Braftovi is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• Strong CYP3A4 inhibitors or inducers: May increase or decrease encorafenib levels.
• Other cancer therapies, such as vemurafenib, which may increase side effects.
• Other cancer therapies, such as bevacizumab or chemotherapy regimens like mFOLFOX6, which may increase toxicity risk.

Braftovi is available in capsule form with dosing based on whether it is used with binimetinib or cetuximab. Also, the recommended dose will depend on the indication, such as metastatic melanoma or metastatic colorectal cancer.

It should be stored at room temperature, away from the reach of children or pets.

Braftovi was originally developed by Array BioPharma and is marketed by Pfizer Inc.

No, there is currently no widely available generic equivalent of Braftovi.

Do not stop taking Braftovi without consulting your healthcare provider. Discontinuation may affect cancer treatment outcomes.

Braftovi may harm an unborn baby, so effective contraception or birth control is recommended during treatment and for a period after stopping therapy. Talk to your doctor if you are already pregnant or if you have any plans to become pregnant. They will know or recommend what is best for you.

It is not known if Braftovi passes into breast milk, so breastfeeding is not recommended during treatment. Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. They will know or recommend what is best for you.